Sialyl Lewis X - a cellular navigation code for targeted inflammation and cancer therapy

Sialyl Lewis It is not only a key molecule for cell surface recognition and signaling, but also a promising core raw material for modern biomedicine, especially in the fields of targeted intervention of inflammatory diseases and cancer immunotherapy.

Chemical Information

Chemical name: Sialyl Lewis X

Common name: Sialyl Lewis X, sLeX

English name: SIALYL LEWIS X

Chemical formula: C31H52N2O23

Molecular weight: 820.74 g/mol

CAS number: 98603-84-0

Structural features

Sialyl Lewis X is a complex tetrasaccharide structure that is unique in that:

Key terminal structure: composed of sialic acid, galactose, N-acetylglucosamine and fucose. The terminal sialic acid-galactose sequence and fucose are the core of biological functions.

Selectin-specific ligand: This structure can be recognized and combined with high affinity by E-selectin and P-selectin, etc., and mediates the initial adhesion and rolling of circulating leukocytes or cancer cells to vascular endothelial cells, which is the initial step of inflammatory response and tumor metastasis.

Main applications and advantages

Target molecules for the treatment of inflammation and autoimmune diseases

Inhibit pathological inflammation: By designing sLeX analogs or mimics, the binding of sLeX on the surface of leukocytes to selectins on vascular endothelial cells can be competitively blocked, thereby effectively inhibiting the excessive recruitment of leukocytes and providing a new targeting strategy for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma.

High specificity and low side effects: Compared with traditional anti-inflammatory drugs, targeting the sLeX-selectin pathway can intervene in the pathological process more precisely and is expected to avoid the side effects caused by systemic immune suppression.

Key tools for cancer diagnosis and antimetastatic therapy

Biomarkers of tumor metastasis: The surface of various cancer cells (such as colon cancer, gastric cancer, and breast cancer) will express abnormally high levels of sLeX, which is closely related to their hematogenous metastasis and poor prognosis. sLeX is an important reference for the development of cancer diagnostic kits and prognostic assessment.

Blocking cancer metastasis: Using sLeX as a target, developing antibodies, small molecule inhibitors or CAR-T cells can interfere with the adhesion between cancer cells and blood vessels, thereby inhibiting the distant metastasis of tumors and opening up a new approach to anti-metastasis treatment.

Core reagents for drug development and basic research

Drug screening and optimization: sLeX is an ideal tool for screening and validating selectin-targeting drugs and can be used to evaluate the binding activity and inhibitory potency of drug candidates.

Immunology research: As a classic molecular model for studying physiological processes such as leukocyte homing and lymphocyte recycling, sLeX is an indispensable research tool in the fields of immunology and cell biology.

Conclusion

Sialyl Lewis From precise anti-inflammation to anti-cancer and anti-metastasis, its application prospects are extremely broad.